{
    "nctId": "NCT02362087",
    "briefTitle": "Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer",
    "officialTitle": "A Multi-Centre Study to Investigate the Natural History of Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Acute Pain",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 75,
    "primaryOutcomeMeasure": "The incidence of TAPS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosed with either invasive breast or prostate cancer (stage I-IV)\n* Age \u226518 years\n* ECOG performance status \u22642\n* Scheduled to receive intravenous taxane-based chemotherapy for either adjuvant or metastatic disease\n* Participants need to have ability to complete questionnaires by themselves or with assistance and have the ability to provide informed written consent\n\nExclusion Criteria:\n\n* Concurrent use of any agents to try to prevent or treat neuropathy or TAPS, including gabapentin, glutamine, vitamin B6, and vitamin E.\n* Pre-existing history of peripheral neuropathy greater than grade 1 NCI CTCAE version 4.0 from any cause (chemotherapy, diabetes, alcohol, toxin, hereditary, etc.) other medical conditions that would make study participation unreasonably hazardous\n* Uncontrolled diabetes\n* Medical or psychiatric illness that would interfere with patients' ability to complete the diary",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}